Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANIRELIX ACETATE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART),Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%).
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (Cr Cl < 30 m L/min).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not approved for use in pediatric patients.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not approved for use in geriatric patients.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
None
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Hypersensitivity reactions (urticaria, angioedema) have been reported,Ovarian hyperstimulation syndrome (OHSS) may occur with ART,Congenital abnormalities cannot be excluded; pregnancy should be excluded before use
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to ganirelix or any component,Known or suspected pregnancy,Lactation (not recommended due to potential neonatal effects)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustments in pregnancy; contraindicated. If inadvertently used, discontinue immediately; no study on pharmacokinetic changes in pregnancy.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Inject exactly as prescribed, typically once daily during the stimulation phase.,Do not skip doses; missed doses may reduce effectiveness.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately.,Store at room temperature (20-25°C) and protect from light.,Use within 30 days after first use.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANIRELIX ACETATE vs ALTAVERA, answered by our medical review team.
GANIRELIX ACETATE is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANIRELIX ACETATE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANIRELIX ACETATE is: 250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANIRELIX ACETATE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANIRELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) . ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.